Virtual Library

Start Your Search

Katy Clarke



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      126P - Regional retrospective analysis of outcomes of EGFR mutated non-squamous non-small cell lung cancer (NSCLC) patients in West Yorkshire (ID 435)

      12:30 - 13:00  |  Author(s): Katy Clarke

      • Abstract
      • Slides

      Background

      In the UK approximately 10% of all patients diagnosed with NSCLC harbour an Epidermal Growth Factor Receptor (EGFR) mutation. Tyrosine kinase inhibitors (TKI) have been used as first-line treatment for this group of patients since 2009. We performed a retrospective analysis of our regional cohort to assess patient outcomes and document changes in practice over the years.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      Electronic paperless notes system (PPM) was used to collect data on 210 patients diagnosed with EGFR mutation positive NSCLC within West Yorkshire from 2009-2018. Information regarding patient characteristics, stage of cancer, treatment, toxicity and outcome was obtained. Descriptive statistics were performed and Graphpad Prism® was used to determine overall survival. Subgroup analyses were performed for exon mutation, performance status, TKI received and year treated.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      Of 150 evaluable patients, 114 received first-line TKI, 3 received second-line TKI and 33 received no TKI. Median age was 72 (interquartile range 62-77). 10, 43 and 61 patients had exon 18, 19 and 21 mutations respectively. 93 patients treated with TKI were performance status (PS) 0-2 and 21 PS 3. 49 patients were treated 2009-13 and 65 2014-2018. Of the 33 patients who did not receive a TKI, 14 had no residual disease following another radical treatment modality, 14 were inappropriate for systemic treatment based on PS or EGFR resistance mutation and 2 declined any treatment. Median overall survival for the full cohort was 15.6 months. Statistically non-significant trends towards improved overall survival were seen in patients with PS ≤ 2 versus (vs.) PS 3 (17.8 vs. 9.9 months); exon 19 vs. 21 (19.1 vs. 14.3 months); treatment with Afatinib vs. Gefitinib or Erlotinib (21.3 vs. 12.8 and 13.8 months) and patients treated 2014-2018 vs. 2009-2013 (18.4 vs. 9.9 months). Compared to 2009-2013, in patients treated 2014-2018 Gefitinib use decreased (40 vs. 23) whilst Erlotinib (9 vs. 18) and Afatinib (0 vs. 24) use both increased.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      Our real-world data supports the published literature by demonstrating improved outcomes with TKI treatment in patients with exon 19 mutations, better PS and treatment more recently with second generation TKIs.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The Leeds Teaching Hospitals NHS Trust.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.